{"filing":{"accession_number":"0001193125-26-326784","cik":"0000034956","ticker":"TENX","company_name":"TENAX THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"d90330d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/34956/000119312526326784/d90330d8k.htm"},"events":[{"id":22787,"run_id":20621,"accession_number":"0001193125-26-326784","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Tenax Therapeutics' financial results for Q2 2026 ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results with condensed consolidated balance sheets and statements of operations showing net loss of $17.8 million for Q2 2026 versus $10.9 million in Q2 2025, along with cash position and operating expense details. This is material to investors as it provides the company's periodic financial performance and cash runway guidance through Q2 2028.","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22837,"accession_number":"0001193125-26-326784","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Tenax Therapeutics' financial results for Q2 2026 ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results with condensed consolidated balance sheets and statements of operations showing net loss of $17.8 million for Q2 2026 versus $10.9 million in Q2 2025, along with cash position and operating expense details. This is material to investors as it provides the company's periodic financial performance and cash runway guidance through Q2 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:25:53.204953+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22837,"accession_number":"0001193125-26-326784","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Tenax Therapeutics' financial results for Q2 2026 ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results with condensed consolidated balance sheets and statements of operations showing net loss of $17.8 million for Q2 2026 versus $10.9 million in Q2 2025, along with cash position and operating expense details. This is material to investors as it provides the company's periodic financial performance and cash runway guidance through Q2 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:25:53.204953+00:00","company_name":"TENAX THERAPEUTICS, INC.","ticker":"TENX","filing_date":"2026-07-31"}]}